Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated endonuclease enzymes (Cas) have revolutionized molecular medicine, genetic engineering, and synthetic biology. While Class 2 Type II Cas9 remains the historical benchmark for targeted genomic editing, the characterization of Type V Cas12 and Type VI Cas13 systems has expanded the precision genome engineering toolkit from double-strand DNA knockouts to single-stranded RNA degradation and diagnostic biosensing.
1. Structural Architecture & Nuclease Domain Organization
The catalytic mechanisms and cleavage profiles of Cas9, Cas12, and Cas13 diverge fundamentally based on their domain architecture, guide RNA (gRNA) requirements, and target nucleic acid substrates:
| CRISPR Nuclease | CRISPR Class / Type | Substrate Target | PAM / PFS Motif | Cleavage Architecture | Collateral Cleavage Activity |
|---|---|---|---|---|---|
| Cas9 (e.g., SpCas9) | Class 2, Type II | Double-Stranded DNA (dsDNA) | 5'-NGG-3' (3' downstream) | Blunt Double-Strand Break (DSB) | None (Strictly Target-Specific) |
| Cas12a (Cpf1) | Class 2, Type V | Double-Stranded DNA (dsDNA) | 5'-TTTV-3' (5' upstream) | Staggered 5-nt 5' Overhang Sticky Ends | Yes (Single-Stranded DNA Trans-Cleavage) |
| Cas13 (e.g., Cas13a/LwaCas13a) | Class 2, Type VI | Single-Stranded RNA (ssRNA) | PFS (Protospacer Flanking Site: 3'-H) | RNA Phosphodiester Hydrolysis | Yes (Single-Stranded RNA Non-Specific Degradation) |
2. Protospacer Adjacent Motif (PAM) Recognition & R-Loop Formation
Target interrogation begins when the Cas endonuclease binds to a specific Protospacer Adjacent Motif (PAM) in the host target genome. For Streptococcus pyogenes Cas9 (SpCas9), recognition of the 5'-NGG-3' PAM initiates local DNA unwinding and directional R-loop propagation from the seed sequence (bases 1–10 adjacent to the PAM) toward the non-seed PAM-distal region.
In contrast, Cas12a recognizes a T-rich 5'-TTTV-3' PAM on the 5' side of the protospacer, making Cas12a particularly advantageous for targeting AT-rich genomic loci, promoter regions, and introns that lack canonical G-rich Cas9 PAM sites.
3. Blunt vs. Staggered Cleavage & DNA Repair Pathways
A primary limitation of canonical Cas9 blunt-end double-strand breaks is the predominance of the Non-Homologous End Joining (NHEJ) repair pathway, which frequently generates unpredictable insertions and deletions (indels) and chromosomal translocations. Cas12a creates a 4-to-5 nucleotide 5' overhang located 18–23 base pairs distal to the PAM sequence. This staggered overhang architecture dramatically promotes precise Homology-Directed Repair (HDR) when paired with single-stranded oligonucleotide donor templates (ssODNs), reducing unguided NHEJ scarring.
4. Cas13 RNA Editing & Diagnostic Biosensing (SHERLOCK & DETECTR)
Unlike Cas9 and Cas12, Cas13 nucleases exclusively target RNA transcripts using twin Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) catalytic domains. Upon target RNA binding, Cas13 undergoes a conformational rearrangement that activates a promiscuous "collateral" ribonuclease activity, cleaving surrounding bystander non-target RNA molecules.
While collateral RNA cleavage presents toxicity challenges in eukaryotic mammalian therapies, it forms the biochemical foundation of ultra-sensitive molecular diagnostics, such as SHERLOCK (Specific High-Sensitivity Enzymatic Reporter UnLOCKing), capable of attomolar viral and pathogen RNA detection in point-of-care bioassays.
Clinical Takeaway for Translational Biologists
For gene knockouts and exon skipping, engineered high-fidelity SpCas9 variants (e.g., SpCas9-HF1, HiFi Cas9) offer established safety records. For targeted gene insertion via HDR or editing AT-rich promoter sequences, Cas12a provides superior precision. For transient viral transcript destruction and oncology without permanent genomic alteration, Cas13 and ADAR-coupled dCas13 base editors represent the gold standard.